85
Participants
Start Date
March 17, 2021
Primary Completion Date
July 9, 2025
Study Completion Date
July 9, 2025
CAB-AXL-ADC
Conditionally active biologic anti-AXL antibody drug conjugate
PD-1 inhibitor
PD-1 inhibitor
NYU Langone Health, New York
Roswell Park, Buffalo
UPMC Cancer Center, Pittsburgh
"IRCCS Osp. Policlinico San Martino Pad Ex microbiologia, stanza 9, 1 piano.", Genoa
European Institute of Oncology (IEO), IRCCS, Milan
University Hospital 12 de Octubre, Madrid
FirstHealth Outpatient Cancer Center, Pinehurst
Medical University of South Carolina- Hollings Cancer Center, Charleston
Augusta University - Georgia Cancer Center, Augusta
Clinica Universidad de Navarra, Pamplona
Florida Cancer Specialists & Research Institute, Fleming Island
Florida Cancer Specialists, West Palm Beach
Moffitt Cancer Center, Tampa
Florida Cancer Specialist, St. Petersburg
Florida Cancer Specialists & Research Institute, Fort Myers
Integrated University Hospital of Verona, Verona
Sarah Cannon Research Institute, Nashville
Norton Cancer Institute, Brownsboro Hospital Campus, Louisville
Baptist Health Systems, Lexington
University of Kentucky, Lexington
Hospital Universitario Virgen de Valme, Seville
Gabrail Cancer Research Center, Canton
The Lindner Research Center at the Christ Hospital, Cincinnati
Santa Maria delle Croci Hospital of Ravenna, Ravenna
University of Michigan Comprehensive Cancer Center, Detroit
Hematology/Oncology Clinic, Baton Rouge
Mary Crowley Cancer Research, Dallas
MD Anderson, Houston
University of Colorado Anschutz Medical Campus, Aurora
Hospital San Giuseppe Moscati, Avellino
Comprehensive Cancer Centers of Nevada, Henderson
OptumCare Cancer Care, Las Vegas
California Research Institute, Los Angeles
USC Norris, Los Angeles
Cedars-Sinai, Los Angeles
American Institute of Research, Whittier
City of Hope - Duarte, Duarte
University of California, San Diego (UCSD) - Moores Cancer Center, San Diego
University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center, Irvine
Dana-Farber Cancer Institute, Boston
Henry Dunant Hospital Center, Athens
Metropolitan Hospital Perseus Healthcare Group SA, Piraeus
Bioclinic Thessaloniki, Thessaloniki
European Interbalkan Medical Center, Thessaloniki
ICON Cancer Centre, Hong Kong
Queen Mary Hospital, Hong Kong
Hong Kong United Oncology Centre, Kowloon
Kaoshiung Chang Gung Memorial Hospital, Kaohsiung City
Taichung Veterans General Hospital, Taichung
National Cheng Kung University Hospital, Tainan City
National Taiwan University Hospital, Taipei
Taipei Veterans General Hospital, Taipei
MED-Polonia, Sp. z o.o. (LLC), Poznan
Institute of Genetics and Immunology GENIM, Lublin
Maria Sklodowska-Curie - National Research Institute of Oncology, Warsaw
Polish Mother's Memorial Hospital-Research Institute, Lodz
Specialistic Oncologic Hospital NU-MED, Tomaszów Mazowiecki
Hospital del Mar, Barcelona
Hospital de la Santa Creu i Sant Pau, Barcelona
Catalan Institute of Oncology, Hospital Duran i Reynals, Barcelona
Lead Sponsor
BioAtla, Inc.
INDUSTRY